- Participants assigned to groups 3 or 4 will undergo the following: Medication: Participants that are placed in the bevacizumab and cyclophosphamide and methotrexate (CM) arm will receive bevacizumab intravenously once every 3 weeks for approximately 6 months, followed by every 6 week treatments for additional 1.5 years; cyclophosphamide orally once a day and methotrexate orally twice a day for the first two days of each week. The treatments with CM therapy and bevacizumab will continue for approximately 6 months. Physical Exams: once 6 weeks of drug therapy (2 cycles)is completed, physical examination frequency is reduced to every 6 weeks (every other cycle) for the additional 6 cycles. Once 24 weeks of drug therapy (8 cycles or about 6 months since the start of therapy) are completed, physical examination will be done every 12 weeks for the duration of protocol therapy. Blood Tests: chemistry and hematology testing will be done prior to start of Cycles 1, 2 and 3 and then every 6 weeks (every other cycle) for the duration of cyclophosphamide and methotrexate chemotherapy. After 24 weeks (8 cycles) of drug treatment, hematology/chemistry testing frequency can be reduced to every 12 weeks (every other cycle) for the rest of bevacizumab treatment. Urine Tests will be done every other cycle for the duration of treatment. Heart function testing by echocardiogram will be done at 6 months, 1, 2, and 3 years after participants start the study. Ultrasound of the blood vessels will be done on those randomized to receive bevacizumab with CM chemotherapy. This test will be done at baseline and after completion of the first and second cycles of therapy.